{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T13:56:21Z","timestamp":1726235781223},"publisher-location":"Cham","reference-count":101,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783319997155"},{"type":"electronic","value":"9783319997162"}],"license":[{"start":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T00:00:00Z","timestamp":1546214400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/978-3-319-99716-2_13","type":"book-chapter","created":{"date-parts":[[2018,12,30]],"date-time":"2018-12-30T16:33:57Z","timestamp":1546187637000},"page":"269-287","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Transplantation"],"prefix":"10.1007","author":[{"given":"Jasmine","family":"Zain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,31]]},"reference":[{"key":"13_CR1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.14694\/EDBK_175437","volume":"37","author":"ES Jaffe","year":"2017","unstructured":"Jaffe ES, Barr PM, Smith SM (2017) Understanding the new WHO classification of lymphoid malignancies: why it\u2019s important and how it will affect practice. Am Soc Clin Oncol Educ Book 37:535\u2013546","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10","key":"13_CR2","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","volume":"105","author":"R Willemze","year":"2005","unstructured":"Willemze R et al (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105(10):3768\u20133785","journal-title":"Blood"},{"issue":"25","key":"13_CR3","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D (2008) International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26(25):4124\u20134130","journal-title":"J Clin Oncol"},{"issue":"7","key":"13_CR4","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/cncr.30416","volume":"123","author":"KR Carson","year":"2017","unstructured":"Carson KR et al (2017) A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer 123(7):1174\u20131183","journal-title":"Cancer"},{"issue":"2","key":"13_CR5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.blre.2015.08.003","volume":"30","author":"J Iqbal","year":"2016","unstructured":"Iqbal J et al (2016) Genomic signatures in T-cell lymphoma: how can these improve precision in diagnosis and inform prognosis? Blood Rev 30(2):89\u2013100","journal-title":"Blood Rev"},{"issue":"7","key":"13_CR6","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A Gallamini","year":"2004","unstructured":"Gallamini A et al (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103(7):2474\u20132479","journal-title":"Blood"},{"issue":"7","key":"13_CR7","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3109\/07357900009032827","volume":"18","author":"AP Jillella","year":"2000","unstructured":"Jillella AP et al (2000) P-glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma. Cancer Invest 18(7):609\u2013613","journal-title":"Cancer Invest"},{"issue":"17","key":"13_CR8","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","volume":"129","author":"YL Kwong","year":"2017","unstructured":"Kwong YL et al (2017) PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase. Blood 129(17):2437\u20132442","journal-title":"Blood"},{"issue":"3","key":"13_CR9","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0190-9622(99)70491-3","volume":"40","author":"HS Zackheim","year":"1999","unstructured":"Zackheim HS et al (1999) Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol 40(3):418\u2013425","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"13_CR10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJM195709122571102","volume":"257","author":"ED Thomas","year":"1957","unstructured":"Thomas ED et al (1957) Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 257(11):491\u2013496","journal-title":"N Engl J Med"},{"issue":"7540","key":"13_CR11","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nature14242","volume":"518","author":"K Busch","year":"2015","unstructured":"Busch K et al (2015) Fundamental properties of unperturbed haematopoiesis from stem cells in vivo. Nature 518(7540):542\u2013546","journal-title":"Nature"},{"issue":"6","key":"13_CR12","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s10875-007-9120-0","volume":"27","author":"DM Brinkman","year":"2007","unstructured":"Brinkman DM et al (2007) Resetting the adaptive immune system after autologous stem cell transplantation: lessons from responses to vaccines. J Clin Immunol 27(6):647\u2013658","journal-title":"J Clin Immunol"},{"issue":"4","key":"13_CR13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood.V49.4.511.511","volume":"49","author":"ED Thomas","year":"1977","unstructured":"Thomas ED et al (1977) One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 49(4):511\u2013533","journal-title":"Blood"},{"issue":"7","key":"13_CR14","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/01.TP.0000129810.77790.EF","volume":"78","author":"S Slavin","year":"2004","unstructured":"Slavin S (2004) Reduced intensity versus truly nonmyeloablative conditioning for stem-cell transplant recipients. Transplantation 78(7):964\u2013965","journal-title":"Transplantation"},{"key":"13_CR15","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1182\/asheducation-2011.1.292","volume":"2011","author":"DL Porter","year":"2011","unstructured":"Porter DL (2011) Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies. Hematol Am Soc Hematol Educ Program 2011:292\u2013298","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"13_CR16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-016-0347-1","volume":"9","author":"A Shimoni","year":"2016","unstructured":"Shimoni A et al (2016) Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. J Hematol Oncol 9(1):118","journal-title":"J Hematol Oncol"},{"issue":"4","key":"13_CR17","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2016-12-755496","volume":"130","author":"MB Pedersen","year":"2017","unstructured":"Pedersen MB et al (2017) DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. Blood 130(4):554\u2013557","journal-title":"Blood"},{"issue":"7","key":"13_CR18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11864-015-0347-3","volume":"16","author":"M Sharma","year":"2015","unstructured":"Sharma M, Pro B (2015) Bone marrow transplantation for peripheral T-cell non-Hodgkins\u2019 lymphoma in first remission. Curr Treat Options Oncol 16(7):34","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"13_CR19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2012.03.011","volume":"39","author":"J Yared","year":"2013","unstructured":"Yared J, Kimball A (2013) The role of high dose chemotherapy and autologous stem-cell transplantation in peripheral T-cell lymphoma: a review of the literature and new perspectives. Cancer Treat Rev 39(1):51\u201359","journal-title":"Cancer Treat Rev"},{"issue":"15_suppl","key":"13_CR20","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1200\/jco.2011.29.15_suppl.6565","volume":"29","author":"A. Beitinjaneh","year":"2011","unstructured":"Beitinjaneh A et al (2011) Autologous stem cell transplantation (ASCT) as upfront or salvage therapy for noncutaneous T-cell lymphoma (TCL): The University of Texas M. D. Anderson Cancer Center (MDACC) experience. In: ASCO Meeting Abstracts, vol 29, no 15 suppl, p 6565","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"13_CR21","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.bbmt.2011.02.008","volume":"17","author":"A Nademanee","year":"2011","unstructured":"Nademanee A et al (2011) High-dose therapy and autologous hematopoietic cell transplantation in peripheral T Cell lymphoma (PTCL): analysis of prognostic factors. Biol Blood Marrow Transpl 17(10):1481\u20131489","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"13_CR22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/bmt.2009.165","volume":"45","author":"A Numata","year":"2010","unstructured":"Numata A et al (2010) Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transpl 45(2):311\u2013316","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"13_CR23","first-page":"218","volume":"26","author":"C Kyriakou","year":"2008","unstructured":"Kyriakou C et al (2008) High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of outcome\u2014lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 26(2):218\u2013224","journal-title":"J Clin Oncol"},{"issue":"1","key":"13_CR24","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.bbmt.2008.11.010","volume":"15","author":"D-H Yang","year":"2009","unstructured":"Yang D-H et al (2009) Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome. Biol Blood Marrow Transpl 15(1):118\u2013125","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"13_CR25","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/sj.bmt.1705712","volume":"40","author":"SD Smith","year":"2007","unstructured":"Smith SD et al (2007) Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transpl 40(3):239\u2013243","journal-title":"Bone Marrow Transpl"},{"issue":"25","key":"13_CR26","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F d\u2019Amore","year":"2012","unstructured":"d\u2019Amore F et al (2012) Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 30(25):3093\u20133099","journal-title":"J Clin Oncol"},{"issue":"6","key":"13_CR27","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.clml.2013.07.005","volume":"13","author":"N Mehta","year":"2013","unstructured":"Mehta N et al (2013) A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission. Clin Lymphoma Myeloma Leuk 13(6):664\u2013670","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"13_CR28","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/0300060516676725","volume":"45","author":"X Han","year":"2017","unstructured":"Han X et al (2017) Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: a single-centre experience. J Int Med Res 45(1):290\u2013302","journal-title":"J Int Med Res"},{"doi-asserted-by":"crossref","unstructured":"Fossard G et al (2017) Role of up-front autologous stem cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol","key":"13_CR29","DOI":"10.1093\/annonc\/mdx787"},{"issue":"1","key":"13_CR30","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","volume":"27","author":"P Reimer","year":"2009","unstructured":"Reimer P et al (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 27(1):106\u2013113","journal-title":"J Clin Oncol"},{"issue":"9","key":"13_CR31","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","volume":"20","author":"P Corradini","year":"2006","unstructured":"Corradini P et al (2006) Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20(9):1533\u20131538","journal-title":"Leukemia"},{"issue":"5","key":"13_CR32","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","volume":"19","author":"S Mercadal","year":"2008","unstructured":"Mercadal S et al (2008) Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 19(5):958\u2013963","journal-title":"Ann Oncol"},{"doi-asserted-by":"crossref","unstructured":"Ahn JS et al (2011) Frontline autologous stem cell transplantation as intensive consolidation in patients with peripheral T cell lymphomas: multicenter phase II trial in Korea. In: Proceedings of ASH Annual Meeting Abstracts, vol 118, no 21, p 4477","key":"13_CR33","DOI":"10.1182\/blood.V118.21.4477.4477"},{"issue":"1","key":"13_CR34","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","volume":"79","author":"J Rodriguez","year":"2007","unstructured":"Rodriguez J et al (2007) Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 79(1):32\u201338","journal-title":"Eur J Haematol"},{"issue":"2","key":"13_CR35","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2141.2007.06783.x","volume":"139","author":"AD Cohen","year":"2007","unstructured":"Cohen AD et al (2007) Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone \u00b1 thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol 139(2):224\u2013233","journal-title":"Br J Haematol"},{"issue":"7","key":"13_CR36","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.dld.2007.03.009","volume":"39","author":"A Al-Toma","year":"2007","unstructured":"Al-Toma A et al (2007) Disappointing outcome of autologous stem cell transplantation for enteropathy-associated T-cell lymphoma. Dig Liver Dis 39(7):634\u2013641","journal-title":"Dig Liver Dis"},{"doi-asserted-by":"crossref","unstructured":"Terras S et al (2012) Allogeneic haematopoietic stem cell transplantation in a patient with cutaneous gamma\/delta-T-cell lymphoma. Acta Dermato-Venereol","key":"13_CR37","DOI":"10.2340\/00015555-1460"},{"unstructured":"NCCN guidelines version 3.2018","key":"13_CR38"},{"issue":"suppl 5","key":"13_CR39","doi-asserted-by":"crossref","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","volume":"26","author":"F. d'Amore","year":"2015","unstructured":"d\u2019Amore F et al (2015) Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v108\u2013v115","journal-title":"Annals of Oncology"},{"issue":"11","key":"13_CR40","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.bbmt.2017.07.027","volume":"23","author":"MA Kharfan-Dabaja","year":"2017","unstructured":"Kharfan-Dabaja MA et al (2017) Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK\/T cell lymphomas: an international collaborative effort on behalf of the guidelines Committee of the American Society for blood and marrow transplantation. Biol Blood Marrow Transplant 23(11):1826\u20131838","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"13_CR41","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/sj.bmt.1704392","volume":"33","author":"KW Zamkoff","year":"2004","unstructured":"Zamkoff KW et al (2004) High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma. Bone Marrow Transpl 33(6):635\u2013638","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"13_CR42","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.bmt.1704367","volume":"33","author":"E Jantunen","year":"2004","unstructured":"Jantunen E et al (2004) Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transpl 33(4):405\u2013410","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"13_CR43","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1080\/10428190412331272749","volume":"45","author":"M Jagasia","year":"2004","unstructured":"Jagasia M et al (2004) Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk Lymphoma 45(11):2261\u20132267","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"13_CR44","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2006.06164.x","volume":"134","author":"T Kewalramani","year":"2006","unstructured":"Kewalramani T et al (2006) Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 134(2):202\u2013207","journal-title":"Br J Haematol"},{"issue":"6","key":"13_CR45","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-007-0254-1","volume":"86","author":"MK Kim","year":"2007","unstructured":"Kim MK et al (2007) High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Ann Hematol 86(6):435\u2013442","journal-title":"Ann Hematol"},{"issue":"25","key":"13_CR46","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","volume":"130","author":"B Pro","year":"2017","unstructured":"Pro B et al (2017) Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood 130(25):2709\u20132717","journal-title":"Blood"},{"issue":"17","key":"13_CR47","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","volume":"123","author":"AJ Moskowitz","year":"2014","unstructured":"Moskowitz AJ, Lunning MA, Horwitz SM (2014) How I treat the peripheral T-cell lymphomas. Blood 123(17):2636\u20132644","journal-title":"Blood"},{"issue":"11","key":"13_CR48","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","volume":"22","author":"P Corradini","year":"2004","unstructured":"Corradini P et al (2004) Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin\u2019s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22(11):2172\u20132176","journal-title":"J Clin Oncol"},{"issue":"14","key":"13_CR49","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","volume":"26","author":"S Gouill Le","year":"2008","unstructured":"Le Gouill S et al (2008) Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 26(14):2264\u20132271","journal-title":"J Clin Oncol"},{"issue":"3","key":"13_CR50","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2011.240","volume":"26","author":"A Dodero","year":"2012","unstructured":"Dodero A et al (2012) Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 26(3):520\u2013526","journal-title":"Leukemia"},{"issue":"4","key":"13_CR51","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.bmt.1705244","volume":"37","author":"R Suzuki","year":"2006","unstructured":"Suzuki R et al (2006) Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transpl 37(4):425\u2013431","journal-title":"Bone Marrow Transpl"},{"issue":"24","key":"13_CR52","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1200\/JCO.2008.20.4628","volume":"27","author":"C Kyriakou","year":"2009","unstructured":"Kyriakou C et al (2009) Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 27(24):3951\u20133958","journal-title":"J Clin Oncol"},{"issue":"8","key":"13_CR53","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3109\/10428194.2011.574754","volume":"52","author":"J Zain","year":"2011","unstructured":"Zain J et al (2011) Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control. Leuk Lymphoma 52(8):1463\u20131473","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"13_CR54","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2141.2010.08210.x","volume":"150","author":"AR Shustov","year":"2010","unstructured":"Shustov AR et al (2010) Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. Br J Haematol 150(2):170\u2013178","journal-title":"Br J Haematol"},{"key":"13_CR55","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/bmt.2011.16","volume":"47","author":"M Delioukina","year":"2012","unstructured":"Delioukina M et al (2012) Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas. Bone Marrow Transpl 47:65\u201372","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"13_CR56","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.bbmt.2008.01.002","volume":"14","author":"M Hamadani","year":"2008","unstructured":"Hamadani M et al (2008) Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect. Biol Blood Marrow Transpl 14(4):480\u2013483","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"13_CR57","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3109\/10428194.2011.645818","volume":"53","author":"JD Goldberg","year":"2012","unstructured":"Goldberg JD et al (2012) Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant. Leuk Lymphoma 53(6):1124\u20131129","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"13_CR58","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/annonc\/mdu515","volume":"26","author":"M Loirat","year":"2015","unstructured":"Loirat M et al (2015) Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center. Ann Oncol 26(2):386\u2013392","journal-title":"Ann Oncol"},{"doi-asserted-by":"crossref","unstructured":"Gibson JF et al (2015) Hematopoietic stem cell transplantation for primary cutaneous gammadelta T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma. J Am Acad Dermatol 72(6):1010\u20135 e5","key":"13_CR59","DOI":"10.1016\/j.jaad.2015.01.003"},{"issue":"8","key":"13_CR60","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood-2009-10-247510","volume":"116","author":"M Hishizawa","year":"2010","unstructured":"Hishizawa M et al (2010) Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood 116(8):1369\u20131376","journal-title":"Blood"},{"issue":"7","key":"13_CR61","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.bbmt.2008.04.014","volume":"14","author":"S Shiratori","year":"2008","unstructured":"Shiratori S et al (2008) A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia\/lymphoma (ATL): clinical impact of graft-versus-leukemia\/lymphoma effect. Biol Blood Marrow Transpl 14(7):817\u2013823","journal-title":"Biol Blood Marrow Transpl"},{"doi-asserted-by":"crossref","unstructured":"Fuji S et al (2018) Role of up-front allogeneic hematopoietic stem cell transplantation for patients with aggressive adult T-cell leukemia-lymphoma: a decision analysis. Bone Marrow Transpl","key":"13_CR62","DOI":"10.1038\/s41409-017-0082-4"},{"issue":"2","key":"13_CR63","first-page":"133","volume":"7","author":"RD Bigler","year":"1991","unstructured":"Bigler RD et al (1991) Autologous bone marrow transplantation for advanced stage mycosis fungoides. Bone Marrow Transpl 7(2):133\u2013137","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"13_CR64","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/sj.bmt.1704411","volume":"33","author":"S Ingen-Housz-Oro","year":"2004","unstructured":"Ingen-Housz-Oro S et al (2004) High-dose therapy and autologous stem cell transplantation in relapsing cutaneous lymphoma. Bone Marrow Transpl 33(6):629\u2013634","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"13_CR65","first-page":"775","volume":"14","author":"P Moreau","year":"1994","unstructured":"Moreau P et al (1994) Autologous bone marrow transplantation using TBI and CBV for disseminated high\/intermediate grade cutaneous non-epidermotropic non-Hodgkin\u2019s lymphoma. Bone Marrow Transpl 14(5):775\u2013778","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"13_CR66","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1046\/j.1365-2141.2001.02919.x","volume":"114","author":"E Olavarria","year":"2001","unstructured":"Olavarria E et al (2001) T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement. Br J Haematol 114(3):624\u2013631","journal-title":"Br J Haematol"},{"key":"13_CR67","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1749-6632.2001.tb03718.x","volume":"941","author":"R Russell-Jones","year":"2001","unstructured":"Russell-Jones R et al (2001) Autologous peripheral blood stem cell transplantation in tumor-stage mycosis fungoides: predictors of disease-free survival. Ann N Y Acad Sci 941:147\u2013154","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"13_CR68","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2230.1995.tb01291.x","volume":"20","author":"JC Sterling","year":"1995","unstructured":"Sterling JC et al (1995) Erythrodermic mycosis fungoides treated with total body irradiation and autologous bone marrow transplantation. Clin Exp Dermatol 20(1):73\u201375","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"13_CR69","first-page":"1188","volume":"140","author":"C Ferra","year":"1999","unstructured":"Ferra C et al (1999) Autologous haematopoietic progenitor transplantation in advanced mycosis fungoides. Br J Dermatol 140(6):1188\u20131189","journal-title":"Br J Dermatol"},{"issue":"7","key":"13_CR70","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/sj.bmt.1705968","volume":"41","author":"RF Duarte","year":"2008","unstructured":"Duarte RF et al (2008) Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transpl 41(7):597\u2013604","journal-title":"Bone Marrow Transpl"},{"issue":"90003","key":"13_CR71","doi-asserted-by":"crossref","first-page":"76iii","DOI":"10.1093\/ndt\/gfg1019","volume":"18","author":"Y. Oyama","year":"2003","unstructured":"Oyama Y et al (2003) Combined radioguided parathyroidectomy and intravenous vitamin D therapy for the treatment of uraemic hyperparathyroidism. Nephrol Dial Transpl 18(Suppl 3):iii76\u201378","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"14","key":"13_CR72","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2009.25.8301","volume":"28","author":"M Duvic","year":"2010","unstructured":"Duvic M et al (2010) Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol 28(14):2365\u20132372","journal-title":"J Clin Oncol"},{"issue":"25","key":"13_CR73","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1200\/JCO.2005.02.774","volume":"23","author":"A Molina","year":"2005","unstructured":"Molina A et al (2005) Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol 23(25):6163\u20136171","journal-title":"J Clin Oncol"},{"issue":"6","key":"13_CR74","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1083-8791(99)70017-0","volume":"5","author":"A Molina","year":"1999","unstructured":"Molina A et al (1999) Remission of refractory Sezary syndrome after bone marrow transplantation from a matched unrelated donor. Biol Blood Marrow Transpl 5(6):400\u2013404","journal-title":"Biol Blood Marrow Transpl"},{"issue":"10","key":"13_CR75","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/archderm.138.10.1359","volume":"138","author":"J Guitart","year":"2002","unstructured":"Guitart J et al (2002) Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma. Arch Dermatol 138(10):1359\u20131365","journal-title":"Arch Dermatol"},{"issue":"8","key":"13_CR76","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.bbmt.2009.04.017","volume":"15","author":"PA Wu","year":"2009","unstructured":"Wu PA et al (2009) A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome. Biol Blood Marrow Transpl 15(8):982\u2013990","journal-title":"Biol Blood Marrow Transpl"},{"doi-asserted-by":"crossref","unstructured":"Paralkar VR et al (2011) Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomas. Bone Marrow Transpl","key":"13_CR77","DOI":"10.1038\/bmt.2011.201"},{"issue":"4","key":"13_CR78","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.det.2015.05.014","volume":"33","author":"P Virmani","year":"2015","unstructured":"Virmani P et al (2015) Hematopoietic stem cell transplant for mycosis fungoides and Sezary syndrome. Dermatol Clin 33(4):807\u2013818","journal-title":"Dermatol Clin"},{"issue":"25","key":"13_CR79","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1182\/blood-2015-12-611830","volume":"127","author":"S Whittaker","year":"2016","unstructured":"Whittaker S, Hoppe R, Prince HM (2016) How I treat mycosis fungoides and Sezary syndrome. Blood 127(25):3142\u20133153","journal-title":"Blood"},{"issue":"1","key":"13_CR80","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1067\/mjd.2002.122188","volume":"47","author":"N Masood","year":"2002","unstructured":"Masood N et al (2002) Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation. J Am Acad Dermatol 47(1):140\u2013145","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"13_CR81","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/sj.bmt.1703872","volume":"31","author":"D Soligo","year":"2003","unstructured":"Soligo D et al (2003) Treatment of advanced mycosis fungoides by allogeneic stem-cell transplantation with a nonmyeloablative regimen. Bone Marrow Transpl 31(8):663\u2013666","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"13_CR82","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaad.2007.12.021","volume":"58","author":"CE Introcaso","year":"2008","unstructured":"Introcaso CE et al (2008) Stem cell transplantation in advanced cutaneous T-cell lymphoma. J Am Acad Dermatol 58(4):645\u2013649","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"13_CR83","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000151510","volume":"120","author":"K Kahata","year":"2008","unstructured":"Kahata K et al (2008) Durable remission of Sezary syndrome after unrelated bone marrow transplantation by reduced-intensity conditioning. Acta Haematol 120(1):14\u201318","journal-title":"Acta Haematol"},{"issue":"1","key":"13_CR84","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/j.clml.2017.11.004","volume":"18","author":"BM Cyrenne","year":"2018","unstructured":"Cyrenne BM et al (2018) Transplantation in the treatment of primary cutaneous aggressive epidermotropic cytotoxic CD8-positive T-cell lymphoma. Clin Lymphoma Myeloma Leuk 18(1):e85\u2013e93","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"13_CR85","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/bmt.2014.161","volume":"49","author":"MJ Lechowicz","year":"2014","unstructured":"Lechowicz MJ et al (2014) Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transpl 49(11):1360\u20131365","journal-title":"Bone Marrow Transpl"},{"issue":"29","key":"13_CR86","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1200\/JCO.2014.57.5597","volume":"32","author":"RF Duarte","year":"2014","unstructured":"Duarte RF et al (2014) Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. J Clin Oncol 32(29):3347\u20133348","journal-title":"J Clin Oncol"},{"doi-asserted-by":"crossref","unstructured":"Belinostat is active in peripheral T-cell lymphoma. Cancer Discov 5(8):795","key":"13_CR87","DOI":"10.1158\/2159-8290.CD-RW2015-125"},{"issue":"12","key":"13_CR88","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/annonc\/mdv473","volume":"26","author":"C Hosing","year":"2015","unstructured":"Hosing C et al (2015) Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol 26(12):2490\u20132495","journal-title":"Ann Oncol"},{"issue":"4","key":"13_CR89","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s12185-013-1410-0","volume":"98","author":"T Nakaike","year":"2013","unstructured":"Nakaike T et al (2013) Reduced-intensity conditioning followed by cord blood transplantation in a patient with refractory folliculotropic mycosis fungoides. Int J Hematol 98(4):491\u2013495","journal-title":"Int J Hematol"},{"issue":"5","key":"13_CR90","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s12185-008-0190-4","volume":"88","author":"T Fukushima","year":"2008","unstructured":"Fukushima T et al (2008) Successful cord blood transplantation for mycosis fungoides. Int J Hematol 88(5):596\u2013598","journal-title":"Int J Hematol"},{"issue":"12","key":"13_CR91","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/j.1346-8138.2010.00985.x","volume":"37","author":"H Tsuji","year":"2010","unstructured":"Tsuji H et al (2010) Two cases of mycosis fungoides treated by reduced-intensity cord blood transplantation. J Dermatol 37(12):1040\u20131045","journal-title":"J Dermatol"},{"issue":"214","key":"13_CR92","doi-asserted-by":"crossref","first-page":"214ra171","DOI":"10.1126\/scitranslmed.3007420","volume":"5","author":"W.-K. Weng","year":"2013","unstructured":"Weng et al (2013) Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma. Sci Transl Med Dec 4; 5(214)","journal-title":"Science Translational Medicine"},{"issue":"6","key":"13_CR93","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.bbmt.2014.02.023","volume":"20","author":"J Benjamin","year":"2014","unstructured":"Benjamin J et al (2014) Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms. Biol Blood Marrow Transpl 20(6):837\u2013843","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"13_CR94","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3109\/10428194.2015.1044748","volume":"57","author":"M Schneeweiss","year":"2016","unstructured":"Schneeweiss M et al (2016) Transformed mycosis fungoides: bridging to allogeneic stem cell transplantation with brentuximab vedotin. Leuk Lymphoma 57(1):206\u2013208","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"13_CR95","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/annonc\/mdg458","volume":"14","author":"WY Au","year":"2003","unstructured":"Au WY et al (2003) Autologous stem cell transplantation for nasal NK\/T-cell lymphoma: a progress report on its value. Ann Oncol 14(11):1673\u20131676","journal-title":"Ann Oncol"},{"issue":"1","key":"13_CR96","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00277-017-3127-2","volume":"97","author":"TSY Chan","year":"2018","unstructured":"Chan TSY et al (2018) PD1 blockade with low-dose nivolumab in NK\/T cell lymphoma failing L-asparaginase: efficacy and safety. Ann Hematol 97(1):193\u2013196","journal-title":"Ann Hematol"},{"issue":"9","key":"13_CR97","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O\u2019Connor","year":"2011","unstructured":"O\u2019Connor OA et al (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29(9):1182\u20131189","journal-title":"J Clin Oncol"},{"issue":"1","key":"13_CR98","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","volume":"109","author":"M Duvic","year":"2007","unstructured":"Duvic M et al (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109(1):31\u201339","journal-title":"Blood"},{"issue":"32","key":"13_CR99","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","volume":"27","author":"RL Piekarz","year":"2009","unstructured":"Piekarz RL et al (2009) Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27(32):5410\u20135417","journal-title":"J Clin Oncol"},{"issue":"19","key":"13_CR100","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363(19):1812\u20131821","journal-title":"N Engl J Med"},{"issue":"29","key":"13_CR101","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1200\/JCO.2010.29.3241","volume":"28","author":"RF Duarte","year":"2010","unstructured":"Duarte RF et al (2010) Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 28(29):4492\u20134499","journal-title":"J Clin Oncol"}],"container-title":["Cancer Treatment and Research","T-Cell and NK-Cell Lymphomas"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-99716-2_13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T18:24:36Z","timestamp":1720895076000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-99716-2_13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,31]]},"ISBN":["9783319997155","9783319997162"],"references-count":101,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-99716-2_13","relation":{},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"type":"print","value":"0927-3042"},{"type":"electronic","value":"2509-8497"}],"subject":[],"published":{"date-parts":[[2018,12,31]]}}}